TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03783507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order 1
Description: Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order 2
Description: Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order 3
Description: Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order 4
Description: Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)
Study: NCT01912066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stillen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotec (reference drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID (Aceclofenac)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID (Aceclofenac)
Study: NCT02611180

Intervention type: PROCEDURE
Intervention: Skin punch biopsy

Intervention type: PROCEDURE
Intervention: Skin punch biopsy

Intervention type: PROCEDURE
Intervention: Peripheral blood draw

Intervention type: PROCEDURE
Intervention: Peripheral blood draw
Study: NCT00807118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 2 x 4 mg tab in formulation F under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 1 x 8 mg tab in formulation F under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 1 x 8 mg tab in formulation E(1) under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 1 x 8 mg tab in formulation F under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 2 x 4 mg tab in formulation F under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 1 x 8 mg tab in formulation F under fasted condition
Study: NCT04970745

Intervention type: OTHER
Intervention: Transcranial parenchymal color Doppler ultrasound (TCS)
Description: tracing the nigrostriatal echogenic area

Intervention type: OTHER
Intervention: Transcranial parenchymal color Doppler ultrasound (TCS)
Description: tracing the nigrostriatal echogenic area

Intervention type: OTHER
Intervention: Transcranial parenchymal color Doppler ultrasound (TCS)
Description: tracing the nigrostriatal echogenic area

Intervention type: OTHER
Intervention: Electromyography (EMG) tremor analysis
Description: observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences

Intervention type: OTHER
Intervention: Electromyography (EMG) tremor analysis
Description: observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences

Intervention type: OTHER
Intervention: Electromyography (EMG) tremor analysis
Description: observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences
Study: NCT04133051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Analgesia Using Bupivacaine 0.25%
Description: With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.~Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses
Study: NCT04157374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation training
Description: They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Exercises
Description: Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Exercises
Description: Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
Study: NCT01702844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
Study: NCT02193776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bedaquiline
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bedaquiline
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bedaquiline
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
Description: oral
Study: NCT04346095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Sedatives with or Without Analgesia
Description: The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Sedatives with or Without Analgesia
Description: The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
Study: NCT01311817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)
Description: 1mL liquid contained in an adhesive skin patch

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)
Description: 1mL liquid contained in an adhesive skin patch
Study: NCT00555412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A - 10 mg loxapine q 4 h x 3 (30 mg total)
Description: loxapine aerosol inhalation high dose regimen (30 mg total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)
Description: loxapine aerosol inhalation middle dose regimen (20 mg total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C - 5 mg loxapine q 4 h x 3 (15 mg total)
Description: loxapine aerosol inhalation low dose regimen (15 mg total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D - inhaled placebo q 4 h x 3
Description: placebo aerosol inhalation (0 mg total)
Study: NCT01269112

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: citrate regional anticoagulation
Description: Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: citrate regional anticoagulation
Description: Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: citrate regional anticoagulation
Description: Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation
Study: NCT00721006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MESENDO
Description: 40 subcutaneous injections of biological product

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 subcutaneous injections of placebo
Study: NCT04834570

Intervention type: BEHAVIORAL
Intervention: Quality of life in Breast Cancer Survivors
Description: The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ - BR-23~* FACT-B
Study: NCT01077635

Intervention type: DRUG
Intervention: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
Description: HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
Study: NCT01139502

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Work rehabilitation based on the cognitive therapeutical model
Description: Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Work rehabilitation with the addition of cognitive training
Description: Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
Study: NCT03675503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Prevention Decision Support
Description: Decision support used by nurses to appropriately provide ambulatory aids to hospitalized patients in order to reduce hospital falls
Study: NCT01295385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUCLEAR MAGNETIC RESONANCE IMAGING
Description: Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NUCLEAR MAGNETIC RESONANCE IMAGING
Description: Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique and to estimate the metabolic and structural abnormalities in this population.
Study: NCT04392739

Intervention type: DRUG
Group type: OTHER
Intervention: Tpoxx
Description: oral antiviral
Study: NCT02159586

Intervention type: DEVICE
Intervention: gastric electrical stimulator
Study: NCT03650621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic acupuncture
Description: 5 magnetic acupuncture stickers will be placed on the infants ear

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: stickers (magnets removed)
Description: in this group 5 stickers (magnets removed) will be placed on the infants ear
Study: NCT04125563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsicum Oleoresin
Description: The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Soft gel capsules filled with placebo - sorbitol and colorant.
Study: NCT04078802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VNOTES/VH
Description: same as above

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VNOTES/VH
Description: same as above
Study: NCT01884077

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Shoulder Arthroplasty
Description: REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Shoulder Arthroplasty
Description: TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
Study: NCT01706458

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sipuleucel-T
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: Given ID
Study: NCT03820609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: This digital application for sexual assault prevention can be completed on a tablet computer.
Study: NCT02760940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral liposomal iron
Description: After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
Study: NCT06579430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green near infrared fluorescence imaging
Description: ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 2.5 mg/mL as recommended by the manufacturer (Verdye). 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patient\&amp;#39;s height and weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green near infrared fluorescence imaging
Description: ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 0.5 or 2.5 mg/mL as recommended by the manufacturer. 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patients height and weight. Different administration rates (fast: 2s, slow: 15-20s) and a different camera system were tested.~Group 1: Quest Platform 2.0; Fast/Slow; 2.5 mg/mL Group 2: Quest Platform 2.0; Slow/Fast; 2.5 mg/mL Group 3: Quest Platform 2.0; Fast/Fast; 2.5 mg/mL Group 4: Stryker Spy-Elite; Fast/Fast; 2.5 mg/mL Group 5: Quest Platform 2.0; Fast/Fast; 0.5 mg/mL
Study: NCT00793858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo, isotonic ciclesonide, hypotonic ciclesonide
Description: 200mcg/nostril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo, isotonic ciclesonide, hypotonic ciclesonide
Description: 200mcg/nostril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo, isotonic ciclesonide, hypotonic ciclesonide
Description: 200mcg/nostril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo, isotonic ciclesonide, hypotonic ciclesonide
Description: 200mcg/nostril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo, isotonic ciclesonide, hypotonic ciclesonide
Description: 200mcg/nostril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, isotonic ciclesonide, hypotonic ciclesonide
Description: 200mcg/nostril
Study: NCT00963417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dual x-ray absorptiometry
Description: Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dual x-ray absorptiometry
Description: Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
Study: NCT03166514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially Available Food Bar

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03326596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1000 mg/10ml normal saline infusion
Description: Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
Study: NCT02201524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 400 mg PF 04965842 daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 200 mg PF 04965842 daily for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo for 4 weeks
Study: NCT03446235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise instruction with motivational interview
Description: An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. In addition to the basic instruction of exercise and nutrition, an exercise physiologist provides individualized exercise instruction with a motivational interviewing skill, which is a different style from traditional persuasive style of communication between the healthcare professionals and patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. Basic instruction about exercise and nutrition is provided at the initial visit.
Study: NCT03324607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperpolarized 129Xe gas MRI
Description: There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevespi Aerosphere
Description: There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
Study: NCT00973726

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose test
Description: Subjects ingest an oral glucose tolerance test.
Study: NCT03979898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASTROSTEM
Description: Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10\^7cells/5mL 15kg \~ 25kg : 1x10\^8cells/10mL 25kg over : 1.5x10\^8cells/15mL
Study: NCT00941941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-mesh Hernia Repair
Description: Non-mesh method for treatment of inguinal hernia without the use of a foreign material (mesh). It involves reinforcement of the weakened posterior wall of inguinal canal with a small, undetached strip of aponeurotic tissue of external

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh Hernia Repair
Description: Mesh method for treatment of inguinal hernias by use of an implant (mesh) to reinforce the weakened posterior wall of the inguinal canal. The mesh is made of polypropylene material.
Study: NCT01958996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study: NCT04681235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on VR
Description: The training is aimed at improving the functioning of the motor sphere, including balance, gait, and upper limb function, as well as increasing the level of motivation and reducing the level of anxiety and depression. Game applications were selected based on therapeutic tasks of motor recovery.